等待开盘 12-06 09:30:00 美东时间
0.000
0.00%
Kezar Life Sciences (NASDAQ:KZR) reported quarterly losses of $(1.53) per share which beat the analyst consensus estimate of $(2.08) by 26.3 percent. This is a 44.96 percent increase over losses of $(2.78) per share from
11-13 05:33
Kezar Life Sciences, Inc. (NASDAQ:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced two presentations from the
11-07 20:08
The latest update is out from Kezar Life Sciences ( ($KZR) ). On October 20, 20...
10-23 04:53
今日重点评级关注:韦德布什:维持Artiva Biotherapeutics"跑赢大市"评级,目标价从18美元升至23美元;巴克莱:维持Cellectis"超配"评级,目标价从4美元升至8美元
10-20 10:03
Kezar Life Sciences Inc : Jefferies Cuts to Hold From Buy; Cuts Target Price to...
10-17 11:47
Kezar Life Sciences, Inc. (NASDAQ:KZR, the Company))), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced regulatory
10-17 04:09
Kezar Life Sciences Inc: Lack Resources to Extend Development Timeline for Zeto...
10-17 04:09
Kezar Life Sciences Inc - Extends Duration of Stockholder Rights Plan
10-17 04:08
The latest announcement is out from Kalamazoo Resources Ltd. ( ($AU:KZR) ). Kal...
08-26 15:28
Kezar Life Sciences ( ($KZR) ) has released its Q2 earnings. Here is a breakdow...
08-14 12:31